Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)

NCT05892432 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication Rybelsus (semaglutide) in adults with alcohol use disorder to see how it affects cravings for alcohol.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 50 people

Who can join Ages 21+ · all sexes

Timeline Started 2024-01 · est. completion 2025-11

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05892432 ↗

Description as written by the study sponsor.

This study is a randomized controlled trial of oral semaglutide among treatment-seeking individuals with AUD. The investigators will randomly assign 50 participants to receive semaglutide (titrated to 7 milligrams (mg) per day) or matched placebo for 8 weeks. The primary aims are to assess the safety and tolerability of semaglutide in this population and to evaluate its effects, relative to placebo, on alcohol cue-elicited craving and alcohol consumption.

Treatments tested

Semaglutide 3 MG [Rybelsus] also known as Rybelsus 3 mg Drug

Semaglutide 3 mg will be taken for the first 4 weeks of the 8-week trial.
Semaglutide 7 MG [Rybelsus] also known as Rybelsus 7 mg Drug

Semaglutide 7 mg will be taken for the second 4 weeks of the 8-week trial.
Placebo Drug

A medically inert placebo medication will be taken for 8 weeks.

Main thing measured	Change in Cue Craving Visual Analog Score
Sponsor	University of Colorado, Denver
Conditions studied	Alcohol Use Disorder
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05892432 ↗